Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Moderna Stock Jumps 7% as Melanoma Vaccine Data Looms in Madrid (2026)

Clinical trial results Company update Drug approval AI-generated analysis

πŸ“ˆ Moderna shares jumped 7% to $241.89 ahead of late-stage melanoma vaccine data presentation at the European Society for Medical Oncology congress in Madrid.

🀝 The company is partnering with Merck on a skin cancer program combining its investigational vaccine intismeran autogene with Merck's immunotherapy Keytruda.

πŸ“Š Previous Phase 2b data showed a 49% reduction in the risk of recurrence or death for patients receiving the combination therapy compared to Keytruda alone.

🏭 Manufacturing is being established in a dedicated Massachusetts facility to support a commercial launch of intismeran autogene.

πŸ“ˆ Management reported an outlook for up to 10% revenue growth in 2026, driven by the potential first-ever cancer product for Moderna.

⚠️ Analysts warn that Moderna's thin revenue base leaves its stock particularly sensitive to the upcoming trial results scheduled for October 24.

πŸ“… The Phase 3 study requires a minimum of 18 months of follow-up, with detailed results expected to arrive on October 24.

πŸ₯ Moderna accounted for just 0.4% of net assets in the Health Care Select Sector SPDR ETF (XLV) as of the latest report.

Bullish Signals
  • Moderna shares surged 7% to $241.89, significantly outpacing the broader healthcare sector and larger drugmakers ahead of critical late-stage cancer data.
  • Previous Phase 2b data demonstrated a 49% reduction in the risk of recurrence or death for patients receiving the combination therapy compared to Keytruda alone.
  • Intismeran represents a potential first-ever cancer product for Moderna, with manufacturing established in a dedicated Massachusetts facility to support commercial launch.
  • Management provided an outlook for up to 10% revenue growth in 2026, indicating confidence in the pipeline's contribution to top-line performance.
Risk Factors
  • Analysts note that Moderna's thin revenue base leaves its stock particularly sensitive to the upcoming trial results, creating high volatility risk.
  • The Phase 3 study requires a minimum of 18 months of follow-up, meaning investors must wait until October 24 for detailed results before confirming efficacy.
Full Analysis
Moderna (MRNA) shares surged 7% to $241.89 as investors anticipated late-stage clinical data for its melanoma vaccine candidate, intismeran autogene, at the European Society for Medical Oncology congress in Madrid. The rally significantly outpaced the broader healthcare sector and larger drugmakers, driven by expectations that the upcoming presentation will validate the combination therapy's efficacy. Moderna is partnering with Merck on this skin cancer program, which pairs its investigational vaccine with Merck's immunotherapy Keytruda. Previous Phase 2b data presented at ASCO showed a 49% reduction in the risk of recurrence or death for patients receiving the combination therapy compared to Keytruda alone following surgery, though overall survival remains under evaluation. Management indicated during its Q2 2026 earnings call that the Phase 3 study requires a minimum of 18 months of follow-up. Intismeran represents a potential first-ever cancer product for Moderna, with manufacturing established in a dedicated Massachusetts facility to support a future commercial launch and an outlook for up to 10% revenue growth in 2026. Despite the stock's strong performance, analysts note that Moderna's thin revenue base leaves its stock particularly sensitive to the upcoming trial results. With detailed results set to arrive on October 24, market participants are watching closely to see if the full data matches prior announcements, as a shortfall could introduce downward pressure given the company's limited financial cushion.